Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human endostatin with neoadjuvant chemotherapy and concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
ChiCTR-ONRC-12002394Phase 4Recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of endostar in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Tumor Hospital Affiliated to Guizhou Medical University. Primary endpoints: Acute side effects and Clinical response rate. Started Dec 2011; status: recruiting.
02
Drugs
endostar
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-ONRC-12002394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12002394.